Are you Dr. Jensen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Mob 4th Floor
Duarte, CA 91010Phone+1 626-301-8993
Summary
- Dr. Michael Jensen, MD is a pediatric hematologist/oncologist in Duarte, California.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1993 - 1996
Children's Hospital-OaklandResidency, Pediatrics, 1990 - 1993
Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Publications & Presentations
PubMed
- 155 citationsLocoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysisNicholas A Vitanza, Adam Johnson, Ashley Wilson, Christopher Brown, Jason K. Yokoyama
Nature Medicine. 2021-07-12 - 237 citationsReporter gene imaging of targeted T cell immunotherapy in recurrent glioma.Khun Visith Keu, Timothy H. Witney, Shahriar S. Yaghoubi, Jarrett Rosenberg, Anita Kurien
Science Translational Medicine. 2017-01-18 - 271 citationsNoninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.Shahriar S. Yaghoubi, Michael C. Jensen, Nagichettiar Satyamurthy, Shradha Budhiraja, David S. Paik
Nature Clinical Practice. Oncology. 2009-01-01
Press Mentions
City of Hope Researchers Achieve Remission Using CAR-T Cell Therapy for Aggressive Brain TumorsDecember 28th, 2016
Grant Support
- Targeted Therapy Of All With Gene-Modified Central Memory T CellsNational Cancer Institute2009–2011
- Clinical Trial: Pilot/Feasibility Study To Evaluate The Safety Of CellularNational Center For Research Resources2008
- Cellular Immunotherapy For Follicular Lymphoma Using CD19- Specific T-CellsNational Cancer Institute2007–2008
- Pilot/Feasibility Study To Evaluate The Safety Of CellularNational Center For Research Resources2007
- Cellular Immunotherapy Of Glioblastoma Multiforme Using AnNational Center For Research Resources2007
- Pilot Feasibility And Safety Study Of Cellular Immunotherapy For Recurrent/RefNational Center For Research Resources2005–2007
- Glioma Immunotherapy Usingengineered T-CellsNational Cancer Institute2005–2006
- CD19 Specific Immunotherapy For Follicular LymphomaNational Cancer Institute2004–2006
- Pilot Feasibility And Safety Study Of Cell ImmunotherapyNational Center For Research Resources2004
- Glioma Immunotherapy Using Engineered T-CellsNational Cancer Institute2004
- Cellular Immunotherapy For Neuroblastoma With CTL ClonesNational Cancer Institute2001–2002
- Targeting Malignant B Cells In Lymphoma And LeukemiaNational Cancer Institute2000–2002
- Core--Metabolic Human Studies--ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases1996
